Keyphrases
IDH-mutant Glioma
100%
Monitoring Biomarker
100%
2-Hydroxyglutarate (2-HG)
100%
Tumor
37%
Glioma
25%
Disease Progression
25%
Disease Biomarker
12%
Disease Burden
12%
Therapeutic Discovery
12%
Older Adults
12%
Rigorous Analysis
12%
Biological Variance
12%
Performance Characteristics
12%
Microdialysates
12%
Access Device
12%
Biological Performance
12%
Treatment-resistant
12%
Lumbar Puncture
12%
Therapeutic Response
12%
RANO Criteria
12%
Unmet Needs
12%
Technical Variability
12%
Cross-sectional Cohort
12%
Validation Analysis
12%
Therapeutic Combinations
12%
Surrogate Outcomes
12%
Property-based
12%
Malignant Cells
12%
AUC Analysis
12%
Technical Performance
12%
Initial Sensitivity
12%
Disease Course
12%
Recurrent Disease
12%
Patient-centered
12%
Disease Monitoring
12%
Personalized Therapy
12%
Response to Therapy
12%
Precision Accuracy
12%
Patient Cohort
12%
Percent Change
12%
Medicine and Dentistry
2 Hydroxyglutaric Acid
100%
Biological Marker
100%
Ganglioglioma
100%
Cerebrospinal Fluid
80%
Neoplasm
30%
Diseases
20%
Disease Exacerbation
20%
Treatment Response
10%
Lumbar Puncture
10%
Disease Burden
10%
Recurrent Disease
10%
Disease Course
10%
Personalized Medicine
10%